

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

27 Jul 2026

### Effect of Terminalia chebula gel in reducing the pain of patients with knee osteoarthritis: triple-blind randomized clinical trial

#### Protocol summary

Reducing knee pain and stiffness and improving quality of life in patients with osteoarthritis

##### Study aim

Determining the effect of Black Helilah gel in reducing the pain of patients with knee osteoarthritis

##### Design

First, after the confirmation of the scientific name, the fruit of the Black Helilah plant is extracted by the maceration method, and the preparation of the gel formulation will be done by a pharmacognosist. In this three-blind clinical trial, after receiving the permission of the ethics committee and informed consent, 78 patients with knee osteoarthritis were selected and randomly divided into 3 groups of 26 people. The first group took placebo gel 3 times a day, the second group took 5% Black Helilah topical gel 3 times a day, and the third group took 1% diclofenac topical gel 3 times a day.

##### Settings and conduct

Our study population is patients with knee osteoarthritis in the age group of 45-75 years old, referring to the teaching clinic of Shahrekord University of Medical Sciences.

##### Participants/Inclusion and exclusion criteria

Entry: age range of 45-75 years and definite diagnosis of osteoarthritis based on diagnostic criteria by a specialist doctor  
Non-entry: absence of simultaneous severe diseases such as metabolic and gastrointestinal diseases, absence of severe infection, absence of pregnancy and breastfeeding and disturbed liver tests, absence of history of old fracture or knee surgery, absence of rheumatoid arthritis and seronegative and seropositive arthropathies, absence of history Intra-articular injection within the last 6 weeks

##### Intervention groups

78 patients with knee osteoarthritis were selected and randomly divided into 3 groups of 26 people. The first group consumes placebo gel 3 times a day, the second group consumes 5% Black Halila topical gel 3 times a day, and the third group consumes 1% diclofenac topical gel 3 times a day.

##### Main outcome variables

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20240406061427N1**

Registration date: **2024-07-15, 1403/04/25**

Registration timing: **prospective**

Last update: **2024-07-15, 1403/04/25**

Update count: **0**

##### Registration date

2024-07-15, 1403/04/25

##### Registrant information

##### Name

Navid Oboudiat

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 3650 5792

##### Email address

st\_navid@skums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2024-07-22, 1403/05/01

##### Expected recruitment end date

2024-10-21, 1403/07/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Effect of Terminalia chebula gel in reducing the pain of patients with knee osteoarthritis: triple-blind randomized clinical trial

**Public title**

Effect of Terminalia chebula gel in reducing the pain of patients with knee arthritis

**Purpose**

Supportive

**Inclusion/Exclusion criteria****Inclusion criteria:**

All patients with a definite diagnosis of osteoarthritis based on diagnostic criteria by a specialist doctor Age range between 45 and 75 years

**Exclusion criteria:**

The presence of simultaneous severe diseases such as metabolic and gastrointestinal diseases Severe infection Pregnancy and breastfeeding and abnormal liver tests History of old fracture or knee surgery Rheumatoid arthritis and seronegative and seropositive arthropathy History of intra-articular injection in the last 6 weeks

**Age**

From **45 years** old to **75 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Investigator
- Data analyst

**Sample size**

Target sample size: **78**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

The random unit The random unit will be an individual participant. Each participant is randomly assigned to one of the two groups of intervention (Black Haliley gel) or control group (placebo gel). Layered randomization In layered randomization, participants are layered based on key variables such as age, gender and primary pain in order to ensure balanced distribution among therapeutic groups. For example, layers are defined by age groups (less than 5 years, 2 years and older), gender (male, female) and primary pain (low, medium, severe). The random sequence of random numbers generated by the computer will be used. This sequence is produced using statistical software such as SPSS, R or SAS to ensure randomness in randomization if the individual is observed, the individual is entered into the intervention group and if the number is even, the control group is entered into the control group. Allocation Concealment: The study coordinator delivers the relevant gel to the participant after completing the initial evaluation of the participant and confirming his or her qualification to participate in the study, and reviewing the allocated

treatment group (intervention/ control).

**Blinding (investigator's opinion)**

Triple blinded

**Blinding description**

The samples prepared by the pharmacognosist colleague are packed in tubes marked with A, B and C so that the researcher, the patient and the statistician of the project are not aware of the content of the three types of tubes A, B and C.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Medical School of Medical Sciences of Shahrekord University of Medical Sciences

**Street address**

Kashani street

**City**

Shahrekord

**Province**

Chahar-Mahal-va-Bakhtiari

**Postal code**

8813833435

**Approval date**

2024-01-03, 1402/10/13

**Ethics committee reference number**

IR.SKUMS.MED.REC.1402.087

**Health conditions studied****1****Description of health condition studied**

knee osteoarthritis

**ICD-10 code**

M19.9

**ICD-10 code description**

Osteoarthritis, unspecified site

**Primary outcomes****1****Description**

knee pain

**Timepoint**

The first, third and the first, third and sixth weeks after the start of the intervention

**Method of measurement**

Based on VAS and WOMAC Patients' pain is measured

through the VAS (Visual Analogue Scale) questionnaire and their performance through the Womac (Western Ontario and McMaster Universities Index) questionnaires.

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

The first intervention group: 26 patients with knee osteoarthritis are selected. The first intervention group consumes 5% Halileh black topical gel 3 times a day locally on the knee. Participants will be informed that the type of treatment they received will not be known to avoid bias. They are also encouraged not to guess which treatment they received during the study.

#### Category

Treatment - Drugs

### 2

#### Description

The second intervention group: 26 patients with knee osteoarthritis are selected. The second intervention group uses diclofenac 1% topical gel 3 times a day.

#### Category

Treatment - Drugs

### 3

#### Description

Control group: 26 patients with knee osteoarthritis are selected. The control group consumes placebo gel 3 times a day.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Hajar Shahrekord Hospital

##### Full name of responsible person

Navid Oboudiat

##### Street address

Parastar St.

##### City

Shahrekord

##### Province

Chahar-Mahal-va-Bakhtiari

##### Postal code

8816754633

##### Phone

+98 913 985 4865

##### Email

nimanianima@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Shahre-kord University of Medical Sciences

##### Full name of responsible person

Elham Reisi

##### Street address

Kashani St.

##### City

Shahrekord

##### Province

Chahar-Mahal-va-Bakhtiari

##### Postal code

8813833435

##### Phone

+98 38 3334 9507

##### Email

navid.1999@yahoo.com

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Shahre-kord University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Shahre-kord University of Medical Sciences

##### Full name of responsible person

Navid Oboudiat

##### Position

Intern

##### Latest degree

Bachelor

##### Other areas of specialty/work

General Practitioner

##### Street address

Molavi St.

##### City

Shahrekord

##### Province

Chahar-Mahal-va-Bakhtiari

##### Postal code

8179947161

##### Phone

+98 31 3650 5792

**Email**

navid.1999@yahoo.com

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Shahre-kord University of Medical Sciences

**Full name of responsible person**

Navid Oboudiat

**Position**

Intern

**Latest degree**

Bachelor

**Other areas of specialty/work**

General Practitioner

**Street address**

Molavi St.

**City**

Shahrekord

**Province**

Chahar-Mahal-va-Bakhtiari

**Postal code**

8179947161

**Phone**

+98 31 3650 5792

**Email**

navid.1999@yahoo.com

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Shahre-kord University of Medical Sciences

**Full name of responsible person**

Navid Oboudiat

**Position**

Intern

**Latest degree**

Bachelor

**Other areas of specialty/work**

General Practitioner

**Street address**

Molavi St.

**City**

Shahrekord

**Province**

Chahar-Mahal-va-Bakhtiari

**Postal code**

8179947161

**Phone**

+98 31 3650 5792

**Email**

navid.1999@yahoo.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

To share the data and documents of this research, only the information related to the main outcome will be shared. Also, files that can be published and do not violate people's privacy will be published.

**When the data will become available and for how long**

The access period will start 6 months after the results are published.

**To whom data/document is available**

Our data will only be available to researchers working in academic and scientific institutions.

**Under which criteria data/document could be used**

If there are conditions, all our data will be shared except personal information of people. The use of our data will only be allowed for similar research and review of our data by other researchers. All those who work in universities and scientific centers and decide to conduct similar research or check the accuracy of our data can access our data.

**From where data/document is obtainable**

In order to receive information, all eligible people can collect data by referring to the person in charge of the project. The contact methods are the email address navid.1999@yahoo.com or the contact number 00989103259963.

**What processes are involved for a request to access data/document**

To receive information after sending the request, the requests will be reviewed within 10 days. If the above conditions are met, the information will be sent to the provided email within 30 days at most.

**Comments**